Compare Aurora Cannabis Inc (ACB) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

VUG trades at $86.68, up 1.38% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF recently executed a 1:6 stock split on April 21, 2026, and declared a $0.09 dividend payable June 30, 2026. Support sits near $85–$86, with resistance at $87–$88. Media coverage highlights its low 0.04% expense ratio and strong performance against active funds, though technology concentration at 56% of assets poses sector risk.

Outlook remains positive given cost efficiency and growth exposure, but investors face volatility from tech reliance and market sentiment shifts. The fund's large-cap focus offers stability, yet macroeconomic pressures could challenge returns. Risks include sector rotation and valuation sensitivity, balanced by long-term growth potential in U.S. equities.